Bariatric surgery: impact on oral aripiprazole and fluoxetine bioavailability – A clinical case

Introduction Bioavailability alterations for pharmacological agents following bariatric operations have been previously reported, although they may vary based on the medication. Here we report the post- bariatric impact of the Roux-en-Y gastric bypass (RYGB) on the bioavailability of aripiprazole using therapeutic drug monitoring (TDM).